, Volume 78, Issue 8, pp 845–849 | Cite as

Tildrakizumab: First Global Approval

  • Anthony Markham
AdisInsight Report


Merck & Company Inc. have developed tildrakizumab (tildrakizumab-asmn; Ilumya™), a high-affinity, humanised IgG1 κ monoclonal antibody that specifically targets interleukin-23 p19, as a treatment for chronic plaque psoriasis. The drug was recently approved for marketing by the US FDA based on positive results from the phase III reSURFACE clinical trial programme in patients with chronic plaque psoriasis. This article summarizes the milestones in the development of tildrakizumab leading to this first approval for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88.CrossRefPubMedGoogle Scholar
  2. 2.
    Merck Sharp & Dohme Corp. Tildrakizumab-asmn (ILUMYA™). US prescribing information. 2018. Accessed 22 Mar 2018.
  3. 3.
    Almirall SL, Sun Pharmaceutical Industries Ltd. Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe [media release]. 24 Mar 2017.
  4. 4.
    Merck A. G. Sun Pharma and Merck Co. Inc. enter into licensing agreement for tildrakizumab [media release]. 27 July 2016.
  5. 5.
    Sun Pharmaceutical Industries Ltd. Almirall and Sun Pharma enter into a license agreement for tildrakizumab in Europe for psoriasis [media release]. 27 July 2016.
  6. 6.
    Khalilieh S, Hodsman P, Xu C, et al. Pharmacokinetics of tildrakizumab (MK-3222), an anti-IL-23 monoclonal antibody, following intravenous or subcutaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol. 2018. Scholar
  7. 7.
    Khalilieh S, Bailey-Smith C, Bodrug I, et al. The effect of tildrakizumab, a High-affinity, selective anti-IL23p19 monoclonal antibody (mAb), on cytochrome P450 (CYP) metabolism [abstract no. 4792]. In: 75th Annual Meeting of the American Academy of Dermatology. 2017.Google Scholar
  8. 8.
    Papp K, Reich K, Blauvelt A, et al. Clinical efficacy of tildrakizumab in patients with chronic plaque psoriasis over 2 years of treatment: results from long-term extensions to 2 phase 3 clinical studies [abstract no. 20 poster]. Skin. 2018;2(Suppl):S4.Google Scholar
  9. 9.
    Elewski B, Menter A, Crowley J, et al. Sustained and improved efficacy of tildrakizumab from week 28 to week 52 in treating moderate-to-severe plaque psoriasis [abstract no. 45 poster]. Skin. 2018;2(Suppl):S22.Google Scholar
  10. 10.
    Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Langley RG, Thaci D, Reich K, et al. Tildrakizumab treatment improved measures of psoriatic arthritis in adults with chronic plaque psoriasis [abstract no. FRI0445]. In: 17th Annual Congress of the European League Against Rheumatism. 2016.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations